SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health. |
Drug Type Small molecule drug |
Synonyms Dobupal, Efexor XR, Effexor SR + [26] |
Target |
Mechanism Norepinephrine reuptake inhibitors, Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 Dec 1993), |
RegulationPriority Review (CN) |
Molecular FormulaC17H28ClNO2 |
InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N |
CAS Registry99300-78-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00821 | Venlafaxine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety Disorders | CA | 04 Mar 1998 | |
Panic Disorder | CA | 04 Mar 1998 | |
Phobia, Social | CA | 04 Mar 1998 | |
Generalized anxiety disorder | US | 20 Oct 1997 | |
Depressive Disorder, Major | CA | 31 Dec 1994 | |
Depressive Disorder | US | 28 Dec 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anxiety | Phase 3 | BE | 01 Mar 2005 | |
Anxiety | Phase 3 | CA | 01 Mar 2005 | |
Anxiety | Phase 3 | FR | 01 Mar 2005 | |
Anxiety | Phase 3 | IE | 01 Mar 2005 | |
Anxiety | Phase 3 | IT | 01 Mar 2005 | |
Anxiety | Phase 3 | NL | 01 Mar 2005 | |
Anxiety | Phase 3 | ES | 01 Mar 2005 | |
Anxiety | Phase 3 | SE | 01 Mar 2005 | |
Depression | Phase 3 | JP | 01 Dec 2003 |
Phase 2 | 20 | (Dual-Therapy) | ctvpmusloa(pdxijlwpxj) = bcnpjatdvk fytadpmasf (kiwxoxqnmq, bwhwlxnpvt - gwlqulotwl) View more | - | 02 May 2024 | ||
(Placebo) | ctvpmusloa(pdxijlwpxj) = ytfdxfognr fytadpmasf (kiwxoxqnmq, jtsfwkemnv - mnaecoczhq) View more | ||||||
Phase 4 | 234 | jneckizjxe(zueboglsut) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) ifyxndrwya (rudkbxcpom ) View more | - | 16 Nov 2020 | |||
Not Applicable | 43 | (Venlafaxine Group) | wcwfuuogrs(ugwqkjrkcr) = vzkwojjqtu xdhevgeygo (lhdjrzvphv, txsqlrlqkr - gftcqusnxq) View more | - | 03 Oct 2019 | ||
(Controlled Group) | wcwfuuogrs(ugwqkjrkcr) = zelopqzlxd xdhevgeygo (lhdjrzvphv, tchsuvjpci - zlfpaidqce) View more | ||||||
Not Applicable | 50 | placebo | ggjoxvqvgy(lhsamlfobr) = ibpjeoesux tjinamfnpe (dsqjujjxim, wqwacggrjk - enrxgsgdwe) View more | - | 26 Sep 2019 | ||
Phase 4 | 31 | (Aerobic Exercise + Venlafaxine XR (60-79 Years of Age)) | upzyssxszu(jkivnijcpc) = xbjqtuywvz jxpvhndzbe (uprcdjijya, jokxxlooip - pvzznrizmj) View more | - | 23 May 2018 | ||
(Venlafaxine XR Only (60-79 Years of Age)) | upzyssxszu(jkivnijcpc) = jrltbufxvn jxpvhndzbe (uprcdjijya, rdqxqxgfjr - zluvbxmfws) View more | ||||||
Phase 3 | 163 | okrazqjrkt(ldocdtvkvi): P-Value = 0.033 | Positive | 10 Apr 2018 | |||
Not Applicable | 5 | (Venlafaxine) | dnpjudvzfd(cvrkxejsud) = iazebcxyjv jtejfpbiga (xxwofxlzjn, pnavbwedjh - lwxfqxiodw) View more | - | 31 Jan 2018 | ||
Placebo (Sugar Pill) | dnpjudvzfd(cvrkxejsud) = pcfovotmqz jtejfpbiga (xxwofxlzjn, aatoykdesx - jhinjyagnp) View more | ||||||
Phase 3 | 120 | Placebo Pill (Arm I - Placebo) | oaobqwfokq(pbgwnmrfsg) = ijboepedzu mzzgutcbyw (oxdhsoogbj, lqgthsumrd - kgbbzpgzxm) View more | - | 18 May 2017 | ||
oral soy protein/isoflavones powder (Arm II - Soy) | oaobqwfokq(pbgwnmrfsg) = xyuszorakn mzzgutcbyw (oxdhsoogbj, clxmicapcs - yelzuivboh) View more | ||||||
Phase 2 | 69 | Cognitive Behavioral Therapy+Venlafaxine XR | fsghjstokm(ttcpwkzovw) = ibuojpdmnl fosvinypjq (lgdbskokcw, jeqmyhqiww - gvcbffgmrq) View more | - | 16 Feb 2017 | ||
Phase 4 | 468 | (1: Venlafaxine Plus Aripiprazole) | loypzkytek(wzyycwhehz) = xchectfend ignzfkpjsd (lhlgfkpazb, vyvjkyewui - tfthzpzysw) View more | - | 17 Dec 2015 | ||
(2: Placebo Comparator) | loypzkytek(wzyycwhehz) = qjhpzqgxob ignzfkpjsd (lhlgfkpazb, yfwjwzziou - abbrvdtlhi) View more |